FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Eansor Norman David
2. Issuer Name and Ticker or Trading Symbol

BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President-Protein Sciences
(Last)          (First)          (Middle)

8100 SOUTHPARK WAY, A-8
3. Date of Earliest Transaction (MM/DD/YYYY)

8/5/2020
(Street)

LITTLETON, CO 80120
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy) $106.59            (2)8/18/2023 Common Stock 14114  14114 D  
Stock Options (Right to Buy) $106.59            (3)8/18/2023 Common Stock 18819  18819 D  
Restricted Stock Units  (1)           (4) (4)Common Stock 2174  2174 D  
Stock Options (Right to Buy) $125.05            (4)8/9/2024 Common Stock 11982  11982 D  
Stock Options (Right to Buy) $125.05            (5)8/9/2024 Common Stock 15976  15976 D  
Restricted Stock Units  (1)           (6) (6)Common Stock 2537  2537 D  
Stock Options (Right to Buy) $177.32            (6)8/8/2025 Common Stock 13550  13550 D  
Stock Options (Right to Buy) $177.32            (7)8/8/2025 Common Stock 18066  18066 D  
Restricted Stock Units  (1)           (8) (8)Common Stock 3151  3151 D  
Stock Options (Right to Buy) $190.41            (8)8/7/2026 Common Stock 15948  15948 D  
Stock Options (Right to Buy) $190.41            (9)8/7/2026 Common Stock 21265  21265 D  
Restricted Stock Units  (1)8/5/2020  A   2575     (10) (10)Common Stock 2575 $0 2575 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   11488     (10)8/5/2027 Common Stock 11488 $0 11488 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   15318     (11)8/5/2027 Common Stock 15318 $0 15318 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   24975     (12)8/5/2027 Common Stock 24975 $0 24975 D  
Stock Options (Right to Buy) $267.87 8/5/2020  A   24975.0     (13)8/5/2027 Common Stock 24975.0 $0 24975.0 D  

Explanation of Responses:
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) Fully exercisable.
(3) Options to purchase 4,705 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 4,704 shares vest on 8/18/2020.
(4) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(5) Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
(6) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(7) Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
(8) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(9) Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
(10) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(11) Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
(12) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
(13) Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Eansor Norman David
8100 SOUTHPARK WAY, A-8
LITTLETON, CO 80120


President-Protein Sciences

Signatures
/s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.8/7/2020
**Signature of Reporting PersonDate

Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bio Techne Charts.